Parkinson's patients get brain transplants of their own cells

NCT ID NCT06422208

ENROLLING_BY_INVITATION Disease control Sponsor: Penelope J. Hallett, Ph.D. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This early-stage trial tests whether transplanting dopamine neurons made from a patient's own stem cells into the brain is safe for Parkinson's disease. Six people aged 55 to 80 with Parkinson's for at least 5 years will receive the cells in a single surgery. The main goal is to check for side effects, but researchers will also monitor motor function changes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: autologous iPSC-derived dopamine neurons
What this could lead to: If successful, this could point toward a new way to replace lost brain cells and improve motor function in Parkinson's disease.
What could go wrong: This is a very early, small safety trial with only 6 people. The procedure involves brain surgery, which carries risks like infection or bleeding. It may not improve symptoms.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PARKINSON DISEASE

Contacts and locations

Locations

Brigham & Women's Hospital

Boston, Massachusetts, 02215, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.